225 related articles for article (PubMed ID: 17459273)
1. Bone metabolism and new targets for intervention.
Akduman B; Crawford ED
Curr Urol Rep; 2007 May; 8(3):233-8. PubMed ID: 17459273
[TBL] [Abstract][Full Text] [Related]
2. Bone-targeting agents in prostate cancer.
Suzman DL; Boikos SA; Carducci MA
Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
[TBL] [Abstract][Full Text] [Related]
3. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer.
Zhang X
Cancer Commun (Lond); 2019 Nov; 39(1):76. PubMed ID: 31753020
[TBL] [Abstract][Full Text] [Related]
4. Skeletal-related events in prostate cancer.
Smith MR
Clin Adv Hematol Oncol; 2012 Aug; 10(8):535-6. PubMed ID: 23073052
[No Abstract] [Full Text] [Related]
5. Agents targeting prostate cancer bone metastasis.
Mohammad KS; Fournier PG; Guise TA; Chirgwin JM
Anticancer Agents Med Chem; 2009 Dec; 9(10):1079-88. PubMed ID: 19719455
[TBL] [Abstract][Full Text] [Related]
6. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
[TBL] [Abstract][Full Text] [Related]
7. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
Tanaka T; Kawashima H; Kuratsukuri K; Sugimura K; Nakatani T
Hinyokika Kiyo; 2006 Jun; 52(6):491-4. PubMed ID: 16848364
[TBL] [Abstract][Full Text] [Related]
8. The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.
Turner CJ; Edwards CM
Curr Osteoporos Rep; 2016 Oct; 14(5):170-7. PubMed ID: 27566487
[TBL] [Abstract][Full Text] [Related]
9. Markers of bone metabolism in prostate cancer.
Smith MR
Cancer Treat Rev; 2006; 32 Suppl 1():23-6. PubMed ID: 16680835
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone and increased survival in metastatic prostate cancer.
Parker C; Sartor O
N Engl J Med; 2011 Aug; 365(8):767. PubMed ID: 21864180
[No Abstract] [Full Text] [Related]
11. Bone targeted therapies in metastatic castration-resistant prostate cancer.
Rajpar S; Fizazi K
Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases.
Hardaway AL; Herroon MK; Rajagurubandara E; Podgorski I
Cancer Metastasis Rev; 2014 Sep; 33(2-3):527-43. PubMed ID: 24398857
[TBL] [Abstract][Full Text] [Related]
13. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
[TBL] [Abstract][Full Text] [Related]
15. [Bone-targeted treatment in prostate cancer].
Géczi L; Sinkovics I
Magy Onkol; 2014 Sep; 58(3):199-203. PubMed ID: 25260084
[TBL] [Abstract][Full Text] [Related]
16. The use of bisphosphonates in the management of bone metastatic prostate cancer.
Mercadante S
Curr Urol Rep; 2002 Jun; 3(3):244-9. PubMed ID: 12084196
[TBL] [Abstract][Full Text] [Related]
17. Use of bisphosphonates in the treatment of prostate cancer.
Olson KB; Pienta KJ
Oncology (Williston Park); 2000 Sep; 14(9):1361-4; discussion 1364-7. PubMed ID: 11033832
[No Abstract] [Full Text] [Related]
18. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
Carducci MA; Jimeno A
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
[TBL] [Abstract][Full Text] [Related]
19. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Berruti A; Tucci M; Terrone C; Scarpa RM; Angeli A; Dogliotti L
J Natl Cancer Inst; 2003 Feb; 95(4):332-3; author reply 333-4. PubMed ID: 12591993
[No Abstract] [Full Text] [Related]
20. Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: a new beginning?
Sartor O
J Clin Oncol; 2009 May; 27(15):2417-8. PubMed ID: 19364953
[No Abstract] [Full Text] [Related]
[Next] [New Search]
